Groundbreaking immune checkpoint inhibitors, specifically those that target the PD-1/PD-L1 axis, have transformed cancer therapy by reigniting the body’s natural immune response to fight cancer cells [75,81,82]. This evidence concerns the gene CD274 and cancer.